MBI to begin phase-III trials for FS069

September 27, 1995

Molecular Biosystems of San Diego plans to begin phase-III clinicaltrials for its FS069 second-generation ultrasound contrast agent.MBI said this month that 200 patients undergoing echocardiographywill be studied for the agent's ability to provide left

Molecular Biosystems of San Diego plans to begin phase-III clinicaltrials for its FS069 second-generation ultrasound contrast agent.MBI said this month that 200 patients undergoing echocardiographywill be studied for the agent's ability to provide left ventricularopacification and to enhance endocardial border delineation. MBIdeveloped Albunex, which is marketed in the U.S. by MallinckrodtMedical. Mallinckrodt also has marketing rights to FS069 (SCAN9/13/95).